Successful clinical trials depend on recruiting the right participants. To demonstrate the impact of a new therapy, investigators need confidence that patients enrolled in the study genuinely have the target disease, while control subjects do not, including at asymptomatic stages where relevant.
For some studies, particularly those involving chronic conditions, disease status at recruitment can be equally important. Researchers may need to identify participants with active disease, those at risk of exacerbation, or those who meet specific biomarker-based criteria. If recruitment criteria are not applied effectively, studies can experience screening inefficiencies, delays in enrolment, and difficulties generating sufficient evidence to assess treatment outcomes.
Lateral flow tests (LFTs) can support clinical trial recruitment by providing rapid information at the point of enrolment, helping investigators identify appropriate participants more efficiently.
Identifying the Right Participants
At the most fundamental level, recruitment requires a clear distinction between eligible patients and suitable control subjects.
In some studies, recruitment goes beyond simply confirming disease presence or absence. Investigators may also need to identify participants with specific disease activity, disease stage, or other protocol-defined characteristics.
Where an appropriately designed LFT can provide relevant information, it may support the identification of individuals who more closely match study requirements.
Assessing Disease Status at Recruitment
This can be particularly important in studies of chronic diseases where exacerbation events contribute to the evidence needed to evaluate a treatment.
If a significant proportion of participants do not experience such events during the trial period, collecting meaningful data may become more difficult. Assessing disease status at the time of recruitment can therefore be an important consideration.
Improving Screening Efficiency
LFTs may also improve screening efficiency when large populations must be assessed to identify a smaller number of eligible participants.
Their speed and ease of use can help streamline recruitment and may support screening in a wider range of healthcare settings, potentially reducing barriers to participation.
Importantly, the role of an LFT within a recruitment strategy should be determined by the objectives of the study and the trial protocol. In some cases, rapid testing may be used for initial screening, while final eligibility decisions may still require confirmatory methods.
Why It Matters
Patient recruitment is one of the most critical determinants of clinical trial success. Efficient enrolment processes can help reduce delays, improve study execution, and ensure that trial populations are aligned with the scientific objectives of the research.
For diagnostics developers, pharmaceutical companies, and clinical researchers, the value of LFTs extends beyond their use in routine healthcare. When appropriately incorporated into recruitment strategies, they can provide practical support for participant identification, screening, and stratification, helping clinical studies begin with the right patients in the right cohorts.
Work with GADx
Exploring lateral flow diagnostics for clinical trials?
Whether you’re investigating screening, participant identification or stratification, we can discuss your study requirements and explore where lateral flow technology may have a role.
